A PHP Error was encountered

Severity: Notice

Message: Undefined index: Res ultsCount

Filename: controllers/Search.php

Line Number: 75

Backtrace:

File: /var/www/html/application/controllers/Search.php
Line: 75
Function: _error_handler

File: /var/www/html/index.php
Line: 320
Function: require_once

Cytotherapy[Journal] Publications | PubFacts

2,118 results match your criteria Cytotherapy[Journal]


Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.

Cytotherapy 2018 Dec 14. Epub 2018 Dec 14.

Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China; Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of major infectious diseases), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.

Background Aims: Cytokine-induced killer (CIK) cells are the most commonly used cellular immunotherapy for multiple tumors. To further confirm whether chemotherapy with CIK cells improves clinical effectiveness and to reveal its optimal use in non-small cell lung cancer (NSCLC), we systematically reevaluated all relevant studies.

Methods: We collected all studies about chemotherapy with CIK cells for NSCLC from the Medline, Embase, Web of Science, China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Data, China Biological Medicine Database (CBM), Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi-CTR), World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and U. Read More

View Article
December 2018

Response to Nature commentary "Clear up this stem-cell mess".

Cytotherapy 2018 Dec 12. Epub 2018 Dec 12.

University-Hospital of Modena and Reggio Emilia, Italy and Chair, ISCT Presidential Task Force on Unproven and Unethical Cell and Gene Therapy, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia, Modena, Italy.

View Article
December 2018
2 Reads

Evaluation of the differentiation status of neural stem cells based on cell morphology and the expression of Notch and Sox2.

Cytotherapy 2018 Dec 27;20(12):1472-1485. Epub 2018 Oct 27.

US Food & Drug Administration, Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies, Silver Spring, Maryland, USA. Electronic address:

Neural stem cells (NSCs) isolated from a variety of sources are being developed as cellular therapies aimed at treating neurodegenerative diseases. During NSC culture and expansion it is important the cells do not differentiate prematurely because this may have an unfavorable effect on product quality and yield. In our study, we evaluated the use of Notch and Sox2 as markers for undifferentiated human and mouse NSCs. Read More

View Article
December 2018

Bioactive factors secreted from mesenchymal stromal cells protect the intestines from experimental colitis in a three-dimensional culture.

Cytotherapy 2018 Dec 27;20(12):1459-1471. Epub 2018 Oct 27.

Graduate Program in Gastroenterology and Hepatology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address:

Background Aims: Although mesenchymal stromal cells (MSCs) have shown therapeutic potential in intestinal tissue repair, controversy concerning their short survival and poor biodistribution in recipient tissues still remains. Therefore, we investigated the paracrine role of MSC in three-dimensional culture of colon with experimental colitis.

Methods: Colitis was induced in mice by oral administration of dextran sulfate sodium (DSS) for 7 days. Read More

View Article
December 2018

Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome.

Cytotherapy 2018 Dec 26;20(12):1445-1458. Epub 2018 Oct 26.

Department of Biology, Faculty of Science, Arak University, Arak, Iran.

Background: Many studies have reported that inflammation and oxidative stress are involved in the pathogenesis of polycystic ovary syndrome (PCOS). Bone marrow mesenchymal stromal cells (BM-MSCs) have anti-oxidant and anti-inflammation properties. In this study, we investigate the beneficial effect of stem cell therapy on folliculogenesis in mice with induced PCOS METHODS: Mouse model of PCOS was performed through daily injection of testosterone enanthate (1 mg/100 g/body weight subcutaneous (s. Read More

View Article
December 2018

Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study.

Cytotherapy 2018 Dec 3. Epub 2018 Dec 3.

Cell-based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Pathology and Cell-based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Objective: Knee osteoarthritis (OA) is a common skeletal impairment that can cause many limitations in normal life activities. Stem cell therapy has been studied for decades for its regenerative potency in various diseases. We investigated the safety and efficacy of intra-articular injection of placental mesenchymal stem cells (MSCs) in knee OA healing. Read More

View Article
December 2018

Isolation of a novel embryonic stem cell cord blood-derived population with in vitro hematopoietic capacity in the presence of Wharton's jelly-derived mesenchymal stromal cells.

Cytotherapy 2018 Dec 4. Epub 2018 Dec 4.

Biohellenika Biotechnology Company, Thessaloniki, Greece; Department of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Background: Recent studies highlight the existence of a population of cord blood (CB)-derived stem cells that bare embryonic features (very small embryonic-like stem cells [VSELs]) as the most primitive CB-stem cell population. In the present study, we present for the first time a novel and high purity isolation method of VSELs with in vitro hematopoietic capacity in the presence of Wharton's jelly-derived mesenchymal stromal cells (WJ-MSCs).

Methods: The experimental procedure includes isolation upon gradually increased centrifugation spins and chemotaxis to Stromal cell-derived factor 1a (SDF-1a). Read More

View Article
December 2018
3.293 Impact Factor

Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency.

Cytotherapy 2018 Dec 6. Epub 2018 Dec 6.

The Arthritis Program, University Health Network, Toronto, Canada;; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada; Cell Therapy Program, University Health Network, Toronto, Canada; Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada. Electronic address:

Mesenchymal stromal cell (MSC) therapies have been pursued for a broad spectrum of indications but mixed reports on clinical efficacy have given rise to some degree of skepticism regarding the effectiveness of this approach. However, recent reports of successful clinical outcomes and regulatory approvals for graft-versus-host disease, Crohn's disease and critical limb ischemia have prompted a shift in this perspective. With hundreds of clinical trials involving MSCs currently underway and an increasing demand for large-scale manufacturing protocols, there is a critical need to develop standards that can be applied to processing methods and to establish consensus assays for both MSC processing control and MSC product release. Read More

View Article
December 2018
1 Read

Morphological profiling using machine learning reveals emergent subpopulations of interferon-γ-stimulated mesenchymal stromal cells that predict immunosuppression.

Cytotherapy 2018 Nov 28. Epub 2018 Nov 28.

Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address:

Background: Although a preponderance of pre-clinical data demonstrates the immunosuppressive potential of mesenchymal stromal cells (MSCs), significant heterogeneity and lack of critical quality attributes (CQAs) based on immunosuppressive capacity likely have contributed to inconsistent clinical outcomes. This heterogeneity exists not only between MSC lots derived from different donors, tissues and manufacturing conditions, but also within a given MSC lot in the form of functional subpopulations. We therefore explored the potential of functionally relevant morphological profiling (FRMP) to identify morphological subpopulations predictive of the immunosuppressive capacity of MSCs derived from multiple donors, manufacturers and passages. Read More

View Article
November 2018
6 Reads

A simple and efficient method for cultivation of limbal explant stem cells with clinically safe potential.

Cytotherapy 2018 Nov 30. Epub 2018 Nov 30.

Institute of Science and Engineering, Bioengineering, Hacettepe University, Ankara, Turkey; Faculty of Engineering, Chemical Engineering Department, Hacettepe University, Ankara, Turkey. Electronic address:

Background: Several methods to cultivate limbal epithelial stem cells (LESCs) in vitro with the support of feeder layers and different growth medium formulations have been established for several years. The initial green medium consists of various ingredients that exhibit a non-optimal level of biosafety, therefore, different modifications have been made to suit it to safe clinical applications. However, the question of which formulation is the most appropriate remains to be answered. Read More

View Article
November 2018
2 Reads

Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process.

Cytotherapy 2018 Nov 30. Epub 2018 Nov 30.

Cellular Therapy Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Adoptive cell therapy of tumor-infiltrating lymphocytes has shown promise for treatment of refractory melanoma and other solid malignancies; however, challenges to manufacturing have limited its widespread use. Traditional manufacturing efforts were lengthy, cumbersome and used open culture systems. We describe changes in testing and manufacturing that decreased the process cycle time, enhanced the robustness of critical quality attribute testing and facilitated a functionally closed system. Read More

View Article
November 2018

Closed loop bioreactor system for the ex vivo expansion of human T cells.

Cytotherapy 2018 Nov 27. Epub 2018 Nov 27.

Center for Surgery, Innovation, and Bioengineering, Department of Surgery, Massachusetts General Hospital and the Shriners Hospitals for Children, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA; Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA. Electronic address:

Background Aim: Translation of therapeutic cell therapies to clinical-scale products is critical to realizing widespread success. Currently, however, there are limited tools that are accessible at the research level and readily scalable to clinical-scale needs.

Methods: We herein developed and assessed a closed loop bioreactor system in which (i) a highly gas-permeable silicone material was used to fabricate cell culture bags and (ii) dynamic flow was introduced to allow for dissociation of activated T-cell aggregates. Read More

View Article
November 2018

Mesenchymal stem cells preconditioned by staphylococcal enterotoxin B enhance survival and bacterial clearance in murine sepsis model.

Cytotherapy 2018 Nov 23. Epub 2018 Nov 23.

Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address:

Sepsis, a health-threatening progressive infectious disease, is the major cause of morbidity and mortality worldwide. Cell therapy using mesenchymal stromal cells (MSCs) is an innovative strategy with excessive therapeutic potential in the treatment of sepsis. Staphylococcal enterotoxin B (SEB) preconditioning aims to prolong the interval of survival of transplanted MSCs which induces the production of cytoprotective agents, anti-apoptotic and anti-inflammatory factors. Read More

View Article
November 2018
1 Read

Cell sheet technology: a promising strategy in regenerative medicine.

Cytotherapy 2018 Nov 22. Epub 2018 Nov 22.

Department of Burns, Nanfang Hospital, Southern Medical University, Baiyun District, Guangzhou, People's Republic of China. Electronic address:

Regenerative medicine is a burgeoning field that is important to combat challenging diseases and functional impairments. Compared with traditional cell therapies with evident shortcomings (e.g. Read More

View Article
November 2018
3 Reads

Optimizing the transport and storage conditions of current Good Manufacturing Practice -grade human umbilical cord mesenchymal stromal cells for transplantation (HUC-HEART Trial).

Cytotherapy 2018 Nov 16. Epub 2018 Nov 16.

Department of Histology and Embryology, Faculty of Medicine, Ankara University, Ankara, Turkey. Electronic address:

Background: The HUC-HEART Trial is a clinical study of intramyocardial delivery of current Good Manufacturing Practice (cGMP)-grade human umbilical cord multipotent stromal cells (HUC-MSCs) in ischemic cardiomyopathy where 2 × 10 cells are administered to peri-infarcted myocardium. Prior to the onset of the trial, we aimed to optimize the transport/storage conditions for obtaining the highest cell viability and proliferation rate of cells to be transplanted.

Methods: Cells were tested after being transported in phosphate-buffered saline (PBS) or Ringer's lactate-based (RL) transport media supplemented with human serum albumin (HSA) and/or hydroxyethyl starch (HES) at two temperatures (2-10°C or 22-24°C). Read More

View Article
November 2018
3 Reads

Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures.

Cytotherapy 2018 Nov 15. Epub 2018 Nov 15.

Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain; Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

Background Aims: Multipotent mesenchymal stromal cell (MSC)-based medicines are extensively investigated for use in regenerative medicine and immunotherapy applications. The International Society for Cell and Gene Therapy (ISCT) proposed a panel of cell surface molecules for MSC identification that includes human leukocyte antigen (HLA)-DR as a negative marker. However, its expression is largely unpredictable despite production under tightly controlled conditions and compliance with current Good Manufacturing Practices. Read More

View Article
November 2018
2 Reads

Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression.

Cytotherapy 2018 Nov 5. Epub 2018 Nov 5.

Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address:

Background: Multiple myeloma (MM) is a hematologic cancer caused by the abnormal expansion of plasma cells, but the exact mechanism underlying MM development is not completely known. Recently, multiple long noncoding RNAs (lncRNAs) were implicated in the regulation of MM development.

Methods: Samples from patients with MM were collected and detected for LINC00461 expression using real-time polymerase chain reaction (PCR). Read More

View Article
November 2018
3 Reads
3.293 Impact Factor

Evaluation of different routes of administration and biodistribution of human amnion epithelial cells in mice.

Cytotherapy 2018 Nov 5. Epub 2018 Nov 5.

Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address:

Placenta is a non-controversial and promising source of cells for the treatment of several liver diseases. We previously reported that transplanted human amnion epithelial cells (hAECs) differentiate into hepatocyte-like cells, resulting in correction of mouse models of metabolic liver disease or acute hepatic failure. As part of preclinical safety studies, we investigated the distribution of hAECs using two routes of administration to efficiently deliver hAECs to the liver. Read More

View Article
November 2018
6 Reads

Autologous bone marrow-derived CD133 cells with core decompression as a novel treatment method for femoral head osteonecrosis: a pilot study.

Cytotherapy 2018 Nov 5. Epub 2018 Nov 5.

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research, Tehran, Iran. Electronic address:

Background: Avascular necrosis (AVN) of femoral head is a progressive bone disease due to ischemia of femoral head; patients experience pain and they can not do normal activity. There is not an effective way to treat the cause of this disease. In recent studies, treatment of this disease using pluripotent stem cell-derived mesenchyme is safe and effective, but this method needs more investigation. Read More

View Article
November 2018
2 Reads

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.

Cytotherapy 2018 Nov 2. Epub 2018 Nov 2.

Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist, Baylor College of Medicine, Houston, Texas, USA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA; Departments of Pediatrics; Pathology and Immunology. Electronic address:

Background Aims: EBV type II latency tumors, such as Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL) and nasopharyngeal carcinoma, express a limited array of EBV antigens including Epstein-Barr nuclear antigen (EBNA)1, latent membrane protein (LMP)1, LMP2, and BamH1-A right frame 1 (BARF1). Adoptive immunotherapy for these malignancies have focused on EBNA1, LMP1 and LMP2 because little is known about the cellular immune response to BARF1.

Methods: To investigate whether BARF1 is a potential T-cell immunotherapy target, we determined the frequency of BARF1-specific T-cell responses in the peripheral blood of EBV-seropositive healthy donor and patients with EBV-positive malignancies, mapped epitopes and evaluated the effector function of ex vivo-generated BARF1-specific T-cell lines. Read More

View Article
November 2018
5 Reads

Immunogenic potential of human bone marrow mesenchymal stromal cells is enhanced by hyperthermia.

Cytotherapy 2018 Dec 31;20(12):1437-1444. Epub 2018 Oct 31.

Adult Stem Cell Section, National Institute of Craniofacial and Dental Research, Bethesda, Maryland, USA. Electronic address:

Background Aims: Bone marrow-derived mesenchymal stromal cells (MSCs) have been reported to suppress T-cell proliferation and used to alleviate the symptoms of graft-versus-host disease (GVHD). MSCs are a mixed cell population and at this time there are no tools to isolate the cells responsible for the T-cell suppression. We wanted to find a way to enhance the immune-modulatory actions of MSCs and tried varying the temperature at which they were cultured. Read More

View Article
December 2018
6 Reads

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Cytotherapy 2018 Dec 29;20(12):1415-1418. Epub 2018 Oct 29.

Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.

Molecular imaging with F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is an established modality for response assessment in patients with lymphoma undergoing treatment. However, patients treated with novel immunotherapies may have false-positive PET/CT findings due to tumor site and systemic inflammation. In particular, treatment with autologous chimeric antigen receptor modified T-cells redirected at CD19 (CTL019 CAR-T cells) is often complicated by "cytokine release syndrome" (CRS) due to a severe systemic inflammatory reaction. Read More

View Article
December 2018
5 Reads

Cytotherapy in the 21 Century.

Authors:
John Barrett

Cytotherapy 2018 Oct;20(10):1203

View Article
October 2018

Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

Cytotherapy 2018 Dec 27;20(12):1427-1436. Epub 2018 Oct 27.

Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. Electronic address:

Background Aims: Mesenchymal stromal cells (MSCs) enhance islet function both in vitro and in vivo, at least in part by secreting ligands that activate islet G-protein coupled receptors (GPCRs). We assessed whether pre-treatment with a defined "cocktail" of MSC-secreted GPCR ligands enhances islet functional survival in vitro and improves the outcomes of islet transplantation in an experimental model of diabetes.

Methods: Isolated islets were cultured for 48 h with ANXA1, SDF-1 or C3a, alone or in combination. Read More

View Article
December 2018
4 Reads

Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility.

Cytotherapy 2018 Dec 27;20(12):1486-1494. Epub 2018 Oct 27.

Laboratory for Cell and Gene Medicine, Stanford University School of Medicine at Stanford University, Stanford, CA USA.

A significant portion of the more than 1000 candidate cell and gene therapy products currently under clinical investigation (clinicaltrials.gov) are born out of academic research centers affiliated with universities, hospitals and non-profit research institutions. Supporting these efforts are myriad academic clinical materials production facilities with more than 40 such facilities currently operational in the United States alone. Read More

View Article
December 2018
2 Reads

Cell, tissue and gene products with marketing authorization in 2018 worldwide.

Cytotherapy 2018 Nov 24;20(11):1401-1413. Epub 2018 Oct 24.

The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA; Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts, USA. Electronic address:

Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. Read More

View Article
November 2018
11 Reads

Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.

Cytotherapy 2018 Nov 22;20(11):1309-1323. Epub 2018 Oct 22.

Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology and Innovative Therapies, Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Napoli, Italy.

Dendritic cells (DCs) are bone marrow-derived immune cells that play a crucial role in inducing the adaptive immunity and supporting the innate immune response independently from T cells. In the last decade, DCs have become a hopeful instrument for cancer vaccines that aims at re-educating the immune system, leading to a potent anti-cancer immune response able to overcome the immunosuppressive tumor microenvironment (TME). Although several studies have indicated that DC-based vaccines are feasible and safe, the clinical advantages of DC vaccination as monotherapy for most of the neoplasms remain a distant target. Read More

View Article
November 2018
4 Reads

Adipose-derived mesenchymal stromal cell transplantation at the graft site improves the structure and function of autografted mice ovaries: a stereological and biochemical analysis.

Cytotherapy 2018 Nov 22;20(11):1324-1336. Epub 2018 Oct 22.

Department of Biology, Faculty of Science, Arak University, Arak, Iran.

Background: Ovarian tissue autografting is a fertility restoration technique that is frequently used in young women with cancer who undergo radio/chemotherapy. A limiting factor in this technique is ischemia-reperfusion (I/R) damage. Because adipose-derived mesenchymal stromal cells (ADMSCs) protect different ischemic tissues against I/R damage, we examined the effect of ADMSC transplantation at the graft site in mice ovary autografting. Read More

View Article
November 2018
5 Reads

Immune regulatory targets of mesenchymal stromal cell exosomes/small extracellular vesicles in tissue regeneration.

Cytotherapy 2018 Dec 20;20(12):1419-1426. Epub 2018 Oct 20.

Institute of Medical Biology, Agency for Science, Technology and Research, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:

Mesenchymal stromal cell (MSC) therapies have demonstrated therapeutic efficacy in a wide-ranging array of tissue injury and disease indications. An important aspect of MSC-mediated therapeutic activities is immune modulation. Consistent with the concentration of MSC therapeutic potency in its secretion, a significant proportion of MSC immune potency resides in the small extracellular vesicles (sEVs) secreted by MSCs. Read More

View Article
December 2018
1 Read

In vitro assessment of cord blood-derived proinsulin-specific regulatory T cells for cellular therapy in type 1 diabetes.

Cytotherapy 2018 Nov 17;20(11):1355-1370. Epub 2018 Oct 17.

Departments of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address:

Background: Antigen-specific regulatory T cells (Tregs) have proven to be effective in reversing established autoimmunity in type 1 diabetes (T1D). Cord blood (CB) can serve as an efficient and safe source for Tregs for antigen-specific immunomodulation in T1D, a strategy that is yet to be explored. Therefore, we assessed the potential of CB in generation of proinsulin (PI)-specific Tregs by using HLA class II tetramers. Read More

View Article
November 2018

Identification of circulating murine CD34OCN cells.

Cytotherapy 2018 Nov 16;20(11):1371-1380. Epub 2018 Oct 16.

Research Services, Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address:

Background Aims: Previous studies identified a circulating human osteoblastic population that expressed osteocalcin (OCN), increased following fracture and pubertal growth, and formed mineralized colonies in vitro and bone in vivo. A subpopulation expressed CD34, a hematopoietic/endothelial marker. These findings led to our hypothesis that hematopoietic-derived CD34OCN cells exist in the circulation of mice and are modulated after fracture. Read More

View Article
November 2018

Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile.

Cytotherapy 2018 Nov 14;20(11):1337-1344. Epub 2018 Oct 14.

Pediatric Cardiology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address:

Background: Bronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited. Mesenchymal stromal cells (MSCs) are a potential therapy for prevention or reversal of BPD.

Series Of Cases: We report on two infants with severe BPD in whom off-label treatment with repeated intravenous doses of allogeneic bone marrow-derived MSCs were administered. Read More

View Article
November 2018
1 Read

Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy.

Cytotherapy 2018 Nov 14;20(11):1289-1308. Epub 2018 Oct 14.

Medicines Evaluation Board College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. Electronic address:

Dendritic cells (DCs) are key connectors between the innate and adaptive immune system and have an important role in modulating other immune cells. Therefore, their therapeutic application to steer immune responses is considered in various disorders, including cancer. Due to differences in the cell source and manufacturing process, each DC medicinal product is unique. Read More

View Article
November 2018
4 Reads

The in vitro growth of a cord blood-derived cell population enriched for CD34 cells is influenced by its cell cycle status and treatment with hydroxyurea.

Cytotherapy 2018 Nov 12;20(11):1345-1354. Epub 2018 Oct 12.

Hematopoietic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, IMSS National Medical Center, Mexico City, Mexico. Electronic address:

Objective: Cell cycle plays a fundamental role in the physiology of hematopoietic stem and progenitor cells. In the present study we used a negative selection system to obtain an immature cell population-enriched for cord blood-derived CD34 cells-and we determined its proliferation, expansion and differentiation patterns as a function of the cell cycle status. The effects of hydroxyurea (HU) were also assessed. Read More

View Article
November 2018

Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial.

Cytotherapy 2018 Oct 11;20(10):1238-1246. Epub 2018 Oct 11.

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran. Electronic address:

Background: The intra-articular implantation of mesenchymal stromal cells (MSCs) as a treatment for knee osteoarthritis (OA) is an emerging new therapy. In this study, patients with knee OA received intra-articular implantations of autologous bone marrow-derived MSCs. We sought to assess the safety and efficacy of this implantation. Read More

View Article
October 2018
7 Reads

Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018.

Cytotherapy 2018 Nov 10;20(11):1381-1400. Epub 2018 Oct 10.

Department of Orthopedic Surgery and Biomedical Engineering Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:

The Signature Series Symposium "Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies-Promise, Facts and Fantasy" was held as a pre-meeting of the 26 International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. Read More

View Article
November 2018
1 Read

Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.

Cytotherapy 2018 Oct 9;20(10):1259-1266. Epub 2018 Oct 9.

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA. Electronic address:

Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients achieving early complete remissions ultimately relapse. Immunosuppressive ligands are expressed on tumor and supportive cells in the tumor microenvironment (TME). Read More

View Article
October 2018
8 Reads

Mesenchymal stromal cells: an opportunity to treat chronic inflammatory intestinal conditions.

Cytotherapy 2018 Oct 3;20(10):1223-1226. Epub 2018 Oct 3.

Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.

View Article
October 2018

Toward a unified "quality" framework for cell-based therapies.

Cytotherapy 2018 Oct 30;20(10):1220-1222. Epub 2018 Sep 30.

Department of Electrical Engineering, University of Texas at Arlington, Arlington, TX 76109, USA. Electronic address:

View Article
October 2018
5 Reads

Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon.

Cytotherapy 2018 Oct 26;20(10):1227-1237. Epub 2018 Sep 26.

Cell-Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Recent advances in immunotherapeutic modalities have profoundly changed the prospect of cancer treatment. These modalities mainly focus on modulating the immune response toward tumor cells by using monoclonal antibodies, cancer vaccines, adoptive cell transfer or combination of these methods. In the last few years, Iranian scientists have conducted several projects in these arenas. Read More

View Article
October 2018
8 Reads

Robust erythroid differentiation system for rhesus hematopoietic progenitor cells allowing preclinical screening of genetic treatment strategies for the hemoglobinopathies.

Cytotherapy 2018 Oct 22;20(10):1278-1287. Epub 2018 Sep 22.

Sickle Cell Branch, National Heart Lung and Blood Institutes/National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Background Aims: γ-globin expression can be induced by various gene modification strategies, which could be beneficial for hemoglobin (Hb) disorders. To translate promising ideas into clinics, large animal models have proven valuable to evaluate safety and efficacy of the approaches; however, in vitro erythroid differentiation methods have not been established to determine whether they can be modeled in nonhuman primates.

Methods: We optimized erythroid differentiation culture to produce high-level adult Hb from rhesus hematopoietic progenitor cells by using low (LC) or high cytokine concentration (HC) protocols with or without feeder cells. Read More

View Article
October 2018
9 Reads

The potential role of exosomes in the diagnosis and therapy of ischemic diseases.

Cytotherapy 2018 Oct 20;20(10):1204-1219. Epub 2018 Sep 20.

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

In the past, exosomes have been thought of as cellular dust. Today, they are thought to be carriers of real biomarkers and intercellular biological information. The composition of exosomes differs according to their source, and the subsequent information they carry, such as protein, microRNA or mRNA, may also be different. Read More

View Article
October 2018
1 Read

Effect of cell therapy with allogeneic osteoblasts on bone repair of rat calvaria defects.

Cytotherapy 2018 Oct 5;20(10):1267-1277. Epub 2018 Sep 5.

Cell Culture Laboratory, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address:

Background Aims: Regenerative medicine strategies based on cell therapy are considered a promising approach to repair bone defects. The aims of this study were to evaluate the effect of subculturing on the osteogenic potential of osteoblasts derived from newborn rat calvaria and the effect of these osteoblasts on bone repair of rat calvaria defects.

Methods: Cells were obtained from 50 newborn rat calvaria, and primary osteoblasts (OB) were compared with first passage (OB-P1) in terms of osteogenic potential by assaying cell proliferation, alkaline phosphatase (ALP) activity, extracellular matrix mineralization and gene expression of the osteoblastic markers RUNX2, ALP, osteocalcin and bone sialoprotein. Read More

View Article
October 2018
7 Reads

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Cytotherapy 2018 Jul 29;20(7):952-963. Epub 2018 Jun 29.

Harvard Medical School, Boston, Massachusetts, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address:

Background Aims: Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells has demonstrated preclinical efficacy in several model systems, including hematological and solid tumors. We present comprehensive data on manufacturing development and clinical production of autologous NKG2D CAR T cells for treatment of acute myeloid leukemia and multiple myeloma (ClinicalTrials.gov Identifier: NCT02203825). Read More

View Article
July 2018
12 Reads

Dual Effect of Glucocorticoid-Induced Tumor Necrosis Factor-Related Receptor Ligand Carrying Mesenchymal Stromal Cells on Small Cell Lung Cancer: A Preliminary in vitro Study.

Cytotherapy 2018 Jul 28;20(7):930-940. Epub 2018 Jun 28.

Department of Stem Cell Sciences, Graduate School of Health Sciences, Center for Stem Cell Research and Development, Hacettepe University, Ankara, Turkey. Electronic address:

Background Aims: TNFR family member glucocorticoid-induced tumor necrosis factor-related receptor (GITR/TNFRSF18) activation by its ligand glucocorticoid-induced TNF-related receptor ligand (GITRL) have important roles in proliferation, death and differentiation of cells. Some types of small cell lung cancers (SCLCs) express GITR. Because mesenchymal stromal cells (MSCs) may target tumor cells, we aimed to investigate the effect of MSCs carrying GITRL overexpressing plasmid on the proliferation and viability of a GITR SCLC cell line (SCLC-21H) compared with a GITR SCLC cell line (NCI-H82). Read More

View Article
July 2018
1 Read

Therapeutic effect of human amniotic epithelial cells in murine models of Hashimoto's thyroiditis and Systemic lupus erythematosus.

Cytotherapy 2018 Oct 31;20(10):1247-1258. Epub 2018 Aug 31.

Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, China; College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, China; Center for Stem Cell and Regenerative Medicine, Hangzhou, China. Electronic address:

Background Aims: The chronic inflammation of autoimmune diseases develops repetitive localized destruction or systemic disorders, represented by Hashimoto's thyroiditis (HT) and Systemic lupus erythematosus (SLE) respectively. Currently, there are no efficient ways to treat these autoimmune diseases. Therefore, it is critically important to explore new therapeutic strategies. Read More

View Article
October 2018
2 Reads

Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications.

Cytotherapy 2018 Sep 29;20(9):1110-1123. Epub 2018 Aug 29.

The Program of Excellence in Glycosciences, Harvard Medical School, Boston, Massachusetts, and the Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

Background: The regenerative and immunomodulatory properties of human mesenchymal stromal cells (hMSCs) have raised great hope for their use in cell therapy. However, when intravenously infused, hMSCs fail to reach sites of tissue injury. Fucose addition in α(1,3)-linkage to terminal sialyllactosamines on CD44 creates the molecule known as hematopoietic cell E-/L-selectin ligand (HCELL), programming hMSC binding to E-selectin that is expressed on microvascular endothelial cells of bone marrow (BM), skin and at all sites of inflammation. Read More

View Article
September 2018
6 Reads

A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore.

Cytotherapy 2018 Sep 19;20(9):1103-1109. Epub 2018 Aug 19.

Singapore Bioimaging Consortium, A*STAR, and Duke-NUS Medical School, Singapore.

We report on a roundtable event hosted in Singapore that sought to identify some of the ethical and regulatory challenges in translating autologous cell-based interventions, particularly those claiming to involve stem cells, into safe and effective therapies and to propose some solutions to encourage responsible innovation with these products. Challenges are identified in the three areas of cell manufacturing and processing, innovative uses of autologous cells in clinical practice and standards of evidence. Proposed solutions are discussed within a co-operative model of statutory laws and regulations that can enable product development with autologous cells and professional codes and standards that can encourage ethical conduct in clinical practice. Read More

View Article
September 2018
6 Reads

An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.

Cytotherapy 2018 Sep 16;20(9):1164-1181. Epub 2018 Aug 16.

Tumor Immunology Laboratory, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.

Background: Many efforts have been devoted to improve the performance of dendritic cell (DC)-based cancer vaccines. Ideally, a DC vaccine should induce robust type 1-polarized T-cell responses and efficiently expand antigen (Ag)-specific cytotoxic T-cells, while being applicable regardless of patient human leukocyte antigen (HLA) type. Production time should be short, while maximally being good manufacturing practice (GMP)-compliant. Read More

View Article
September 2018
6 Reads

Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.

Cytotherapy 2018 Sep 17;20(9):1182-1190. Epub 2018 Aug 17.

Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. Electronic address:

Background: Restoration of virus-specific immunity by virus specific T cells (VSTs) offers an attractive alternative to conventional drugs, and can be highly effective in immunocompromised patients, including hematopoietic stem cell transplant (HSCT) recipients. However, conventional VSTs manufacture requires preparation of specialized antigen-presenting cells (APCs), prolonged ex vivo culture in serum-containing medium and antigen re-stimulation with viruses or viral vectors to provide viral antigens for presentation on APCs.

Methods: To simplify this complex process, we developed a method to generate multiple VSTs by direct stimulation of peripheral blood mononuclear cells (PBMCs) with overlapping peptide libraries in serum-free medium. Read More

View Article
September 2018
3 Reads